Effects of probiotic fermented milk on symptoms and intestinal flora in patients with irritable bowel syndrome: A randomized, placebo-controlled trial

Scandinavian Journal of Gastroenterology

Volumn 46, Issue 6, 2011, Pages 663-672

  Søndergaard, Bo ^a,d   Olsson, Johan ^b   Ohlson, Kajsa ^c   Svensson, Ulla ^c   Bytzer, Peter ^d   Ekesbo, Rickard ^e  

^a GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^b KPL Good Food Practice AB   (Sweden)

^c Arla Foods   (Denmark)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e Dalby Health Centre   (Sweden)

Author keywords

acidified milk; irritable bowel syndrome; probiotics; RCT

Indexed keywords

PLACEBO; PROBIOTIC AGENT;

ADULT; AGED; ARTICLE; BIFIDOBACTERIUM ANIMALIS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FECES ANALYSIS; FEMALE; FERMENTED MILK; FERMENTED PRODUCT; FOOD INTAKE; HUMAN; INTESTINE FLORA; IRRITABLE COLON; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS PARACASEI; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE;

ABDOMINAL PAIN; ADULT; AGED; ANIMALS; BIFIDOBACTERIUM; DOUBLE-BLIND METHOD; FEMALE; FERMENTATION; HUMANS; INTESTINAL MUCOSA; IRRITABLE BOWEL SYNDROME; LACTOBACILLUS; MALE; MIDDLE AGED; MILK; PAIN MEASUREMENT; PROBIOTICS; TREATMENT OUTCOME;

EID: 79955979294     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521.2011.565066     Document Type: Article

References (19)

1. Cain KC, Headstrom P, Jarrett ME, Motzer SA, Park H, Burr RL, et al. Abdominal pain impacts quality of life in women with irritable bowel syndrome. Am J Gastroenterol 2006;101(1):124-32. (Pubitemid 43381719)
2. Cremonini F, Talley NJ. Irritable bowel syndrome: epidemiology, natural history, health care seeking and emerging risk factors. Gastroenterol Clin North Am 2005;34(2): 189-204. (Pubitemid 40615950)
3. Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Muller-Lissner SA. Functional bowel disorders and functional abdominal pain. Gut 1999; 45(Suppl 2):II43-II47. (Pubitemid 29434812)
4. Cremonini F, Delgado-Aros S, Camilleri M. Efficacy of alsetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials. Neurogastroenterol Motil 2003;15(1):79-86. (Pubitemid 36313138)
5. Evans BW, Clark WK, Moore DJ, Whorwell PJ. Tegaserod for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2004;(1):CD003960.
6. Salminen S, Bouley C, Boutron-Ruault MC, Cummings JH, Franck A, Gibson GR, et al. Functional food science and gastrointestinal physiology and function. Br J Nutr 1998; 80(Suppl 1):S147-71.
7. O'Mahony L, McCarthy J, Kelly P, Hurley G, Luo F, Chen K, et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005;128(3): 541-51. (Pubitemid 40585355)
8. McFarland LV, Dublin S. Meta-analysis of probiotics for the treatment of irritable bowel syndrome. World J Gastroenterol 2008;14(17):2650-61.
9. Moayyedi P, Ford AC, Talley NJ, Cremonini F, Foxx- Orenstein A, Brandt L, et al. The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut 2010;59:325-32.
10. Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther 1997;11(2):395-402. (Pubitemid 27183522)
11. O'Donnell LJ, Virjee J, Heaton KW. Detection of pseudodiarhoea by simple clinical assessment of intestinal transit rate. BMJ 1990;300(6722):439-40. (Pubitemid 20069266)
12. Monsbakken KW, Vandvik PO, Farup PG. Perceived food intolerance in subjects with irritable bowel syndrome - etiology, prevalence and consequences. Eur J Clin Nutr 2006;60(5):667-72. (Pubitemid 43922887)
13. Simren M, Mansson A, Langkilde AM, Svedlund J, Abrahamsson H, Bengtsson U, et al. Food-related gastrointestinal symptoms in the irritable bowel syndrome. Digestion 2001;63(2):108-15. (Pubitemid 32221204)
14. Wang LH, Fang XC, Pan GZ. Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis. Gut 2004;53(8):1096-101.
15. Kristjansson G, Venge P, Wanders A, Loof L, Hallgren R. Clinical and subclinical intestinal inflammation assessed by the mucosal patch technique: studies of mucosal neutrophil and eosinophil activation in inflammatory bowel diseases and irritable bowel syndrome. Gut 2004;53(12):1806-12. (Pubitemid 39556901)
16. Bijkerk CJ, de Wit NJ, Muris JW, Jones RH, Knottnerus JA, Hoes AW. Outcome measures in irritable bowel syndrome: comparison of psychometric and methodological characteristics. Am J Gastroenterol 2003;98(1):122-7. (Pubitemid 36135180)
17. Guyonnet D, Chassany O, Ducrotte P, Picard C, Mouret M, Mercier CH, et al. Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, doubleblind, controlled trial. Aliment Pharmacol Ther 2007;26(3): 475-86. (Pubitemid 47063138)
18. Simren M, Ohman L, Olsson J, Svensson U, Ohlson K, Posserud I, et al. Clinical trial: the effect of a fermented milk containing three probiotic bacteria in patients with irritable bowel syndrome (IBS) - a randomized, double-blind, controlled study. Aliment Pharmacol Ther 2010;31:922-33.
19. Brenner DM, Moeller MJ, Chey WD, Schoenfeld PS. The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review. Am J Gastroenterol 2009; 104(4):1033-49.